Tissue Therapies (TIS)Product: VitroGroTarget Audience: venous...

Tissue Therapies (TIS)

Product: VitroGro
Target Audience: venous ulcer patients + burns + cuts
Results: Successful clinical results through Canada, Australia and now Europe whilst enhancing product (further clinical results due to be released this month for Europe)
Competition: None, we are a monopoly. We previously had one competitor but its product recently failed. This competitor recieved $500 million from its commercial partner. Millions of amputations occur yearly because of venous ulcers and so do millions of surgeries world-wide to remove these ulcers (they grow back as well and are extremely painful).
Commercial Partner: None, large interest with many parties - annoucement due Novemeber, 2011
Sales: Expected to begin in Europe, 2nd quarter 2012
Patents: world-wide - australia, canada, US, europe etc
FDA approval for production: expected soon (2 consultants previous on the FDA board believe that our product will be successful, this will open up the US market).
Manufacturing: Cheap and already begun (think of a bandaid)
Market CapitalisationL: $75 million
Debt: Nil
Cash: >10 million
Directors: World renouned professors
Product ownership: 100%

Disclosure: I hold but not enough.